The published record on SLU-PP-332 consists of cell-based and rodent studies from the Burris laboratory at Saint Louis University, chiefly Billon and colleagues in ACS Chemical Biology in 2023, which report sub-micromolar activation of ERRα, ERRβ and ERRγ in reporter assays, ERRα-dependent induction of oxidative-metabolism genes in C2C12 myotubes, and changes in skeletal-muscle gene expression in mice; there are no human studies. This guide reads that literature neutrally, separating what was measured from how it has been summarised elsewhere, so that a laboratory can cite the work accurately when planning experiments with SLU-PP-332.
Where does SLU-PP-332 come from?
The compound emerged from a medicinal-chemistry program aimed at synthetic ligands for the estrogen-related receptors, orphan nuclear receptors with no known endogenous hormone. Earlier work from the same group had identified acylhydrazone scaffolds as ERR modulators; SLU-PP-332 was selected as a pan-agonist that activates all three isoforms. A note on citation: the titles of the primary papers contain outcome-oriented wording that is not reproduced here. The papers are cited by author, journal and year so that the data can be found without that wording being carried into a methods section.
What was shown in reporter assays?
Cells co-transfected with an ERR isoform and an ERR-responsive luciferase reporter were exposed to a concentration series of SLU-PP-332. Each isoform responded in a concentration-dependent manner, with half-maximal activation reported in the roughly 0.1–0.4 µM range and ERRα the most sensitive. Selectivity was assessed against related nuclear receptors, with the compound reported as inactive at the estrogen receptor despite the ERR name. These assays establish the compound as a direct ERR agonist and provide the reference concentrations that later cell experiments used.
What was shown in cultured muscle cells?
In C2C12 myotubes, SLU-PP-332 increased expression of a set of ERR target genes associated with mitochondrial biogenesis and fatty-acid oxidation, including the coactivator PGC-1α and genes of the oxidative program, measured by quantitative PCR. Knockdown of ERRα blunted the response, which is the key mechanistic control: it shows the gene changes run through the receptor rather than through an off-target route. Respiration measurements on treated cells reported increases in oxygen-consumption rate consistent with the transcriptional data. This is the body of evidence a laboratory reproduces first; the assay designs are described in mitochondrial respiration assays for ERR agonists and gene-expression assays in vitro.
What was shown in rodents?
The 2023 paper and the 2024 follow-up report studies in which mice received the compound and skeletal-muscle tissue was analysed. The authors describe induction of the same oxidative gene program in muscle, increased markers of mitochondrial content, and a shift in fibre-type markers toward the oxidative type, and they use the phrase "exercise mimetic" to describe that gene-expression pattern because it resembles the transcriptional response to endurance exercise. These are tissue-level molecular findings in mice. Whole-animal phenotype measurements in the 2024 work are reported in a metabolic context that is outside the scope of in vitro research and is not summarised here.
What has not been shown?
- No human data. There are no published human studies of SLU-PP-332 of any kind.
- No outcome in the in vitro sense. "Exercise mimetic" is a label for a gene-expression signature, not a measured outcome; it should be quoted with attribution ("described by the authors as") and never as a property of the material.
- Limited independent replication. The primary data come from one research group; independent cell-based replications are beginning to appear but remain few.
- No long-term stability data in solution. The papers use freshly prepared DMSO stocks; solution stability has to be managed in the laboratory as described in solubility and stock solutions.
How should the literature be cited in a methods section?
By author, journal, year, volume and pages, with the compound identified as "SLU-PP-332 (CAS 303760-60-3), a synthetic ERRα/β/γ agonist". The concentrations used in the primary cell work (low micromolar, typically 1–10 µM for 24–48 hours in myotubes) are a sensible starting range for a replication, run alongside vehicle and an ERRα inverse agonist as controls. The metabolic research compounds overview places SLU-PP-332 among the other compounds used in this area.
Sources
- Billon C, et al. ACS Chemical Biology. 2023;18(4):756–771. (Primary report of SLU-PP-332 as an ERR pan-agonist: reporter assays, C2C12 myotubes, mouse skeletal muscle.)
- Billon C, et al. J Pharmacol Exp Ther. 2024;388(2):232–240. (Rodent follow-up from the same group.)
- National Center for Biotechnology Information. PubChem Compound Summary for CID 5338394, SLU-PP-332.
Related research guides
- Is SLU-PP-332 a peptide? A small-molecule ERR agonist explained
- Mitochondrial respiration assays for ERR agonists
- SLU-PP-332: a novel ERR agonist in in vitro research
- SLU-PP-332 vs SLU-PP-915
- Metabolic research compounds: an in vitro overview
Research-use note
All materials discussed are supplied for in vitro laboratory research use only, and are not for human or animal use.
